Risky communication in atherosclerosis and thrombus formation

Merlijn J P M T Meens1, Anna Pfenniger, Brenda R Kwak

  • 1Department of Pathology and Immunology, University of Geneva, Switzerland.

Swiss Medical Weekly
|April 7, 2012
PubMed

Insights

A specific genetic variation in the GJA4 gene, linked to connexin37 (Cx37), increases the risk of atherosclerosis and heart attack. This review explores how this GJA4 single nucleotide polymorphism (SNP) contributes to arterial disease.

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Molecular Biology

Background:

  • Atherosclerosis is a leading cause of death globally, characterized by arterial wall lesions involving lipid and cell accumulation.
  • Risk factors include lifestyle choices and genetic predispositions.
  • A single nucleotide polymorphism (SNP) in the GJA4 gene, encoding connexin37 (Cx37), is associated with increased atherosclerosis risk.

Purpose of the Study:

  • To review current evidence linking the GJA4 SNP to atherosclerosis.
  • To discuss mechanisms connecting the GJA4 SNP to thrombus formation after plaque rupture.

Main Methods:

  • Literature review of epidemiological studies and mechanistic research.
  • Analysis of the functional impact of the GJA4 SNP on Cx37 protein.

Main Results:

  • The GJA4 SNP results in a proline-to-serine substitution in Cx37's C-terminus.
  • This alteration affects the regulatory properties of Cx37 gap junctions and hemi-channels.
  • Evidence suggests a link between this SNP and atherosclerosis development and plaque instability.

Conclusions:

  • The GJA4 SNP is a significant genetic risk factor for atherosclerosis.
  • Understanding the molecular mechanisms is crucial for developing targeted therapies.
  • Further research is needed to fully elucidate the role of Cx37 dysfunction in cardiovascular disease.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...